The G(-248)A polymorphism in the promoter region of the Bax gene was recently associated with low Bax expression, more advanced stage, treatment resistance and short overall survival in B-cell chronic lymphocytic leukemia (CLL), the latter particularly in treated patients. To investigate this further, we analyzed 463 CLL patients regarding the presence or absence of the G(-248)A polymorphism and correlated with overall survival, treatment status and known prognostic factors, for example, Binet stage, V H mutation status and genomic aberrations. In this material, similar allele and genotype frequencies of the Bax polymorphism were demonstrated in CLL patients and controls (n ¼ 207), where 19 and 21% carried this polymorphism, respectively, and no skewed distribution of the polymorphism was evident between different Binet stages and V H mutated and unmutated CLLs. Furthermore, no difference in overall survival was shown between patients displaying the G(-248)A polymorphism or not (median survival 85 and 102 months, respectively, P ¼ 0.21), and the polymorphism did not influence outcome specifically in treated CLL. Neither did the polymorphism affect outcome in prognostic subsets defined by V H mutation status or genomic aberrations. In conclusion, the pathogenic role and clinical impact of the Bax polymorphism is limited in CLL.
Introduction
B-cell chronic lymphocytic leukemia (CLL) is a disease characterized by an accumulation of long-lived tumor B-cells with defects in apoptosis, which is believed to play an important role in disease development. One of the key mechanisms in apoptosis regulation is the balance between members of the proand antiapoptotic B-cell lymphoma-2 (Bcl-2) family of proteins, and various Bcl-2 family members have been associated with dysregulated apoptosis in CLL including Bcl-2, Bax and Mcl-1.
1-3
The antiapoptotic Bcl-2 protein is highly expressed in most CLLs 4 and its expression level has been suggested to correlate with outcome since patients with high Bcl-2 expression show worse prognosis. 5 Bax is a proapoptotic protein which is upregulated in response to chemotherapy and seems to play an important role in drug-induced apoptosis. 1, 3 Bax can heterodimerize with both Bcl-2 and Mcl-1, where overexpression of the latter antiapoptotic proteins can overcome the proapoptotic features of Bax. 6 A high Bcl-2/Bax ratio and high levels of Mcl-1 has consequently been associated with progressive disease and resistance to drug-induced apoptosis. 1, 7 Recently, a single nucleotide polymorphism located within the 5 0 -untranslated region of the promoter of the Bax gene, G(-248)A, was reported to correlate with reduced expression of Bax, progression of disease stage and treatment resistance in CLL. 8 Saxena et al. 8 identified this polymorphism in 2002 and found it over-represented in CLL compared to normal controls, particularly in advanced disease stages; 69% of CLL patients with Rai stage I-IV (11/16) were heterozygous for the G(-248)A polymorphism compared to only B5% of stage 0 patients (1/18) and 4% in healthy controls (1/25) . They could also demonstrate that this polymorphism was associated with reduced Bax protein expression and failure to achieve complete remission by conventional treatment. 8 The G(-248)A polymorphism was thereafter shown to reduce the expression of the Bax promoter. 9 However, in a recent study of 203 CLL patients, Starczynski et al. 10 could not find any increased allele frequency of the Bax polymorphism in CLL compared to healthy controls. On the other hand, they interestingly revealed that this polymorphism was associated with shorter overall survival in CLL, especially in treated patients (14 with and 52 without the polymorphism, P ¼ 0.03). 10 To study this further, we investigated the Bax G(-248)A polymorphism status in a large cohort of CLL (463 cases) patients and healthy controls (207 individuals) and correlated with overall survival and known prognostic markers such as Binet stage, the immunoglobulin (Ig) V H gene mutation status and genomic aberrations (11qÀ, þ 12, 13qÀ, 17pÀ). [11] [12] [13] [14] We also studied the effect of the Bax polymorphism on Bax expression levels by real-time quantitative (RQ)-PCR in a subset of patients and on outcome in treated CLL patients.
Patients, materials and methods

Patients and materials
Tumor samples, collected from 463 patients with CLL, were identified from the archives of frozen tissue specimens at University Hospitals of Uppsala (n ¼ 145), Linkö ping (n ¼ 54), Umeå (n ¼ 35), Stockholm (n ¼ 15), Sweden, Ulm, Germany (n ¼ 181), and Tampere (n ¼ 33), Finland. Frozen tumor material was obtained from mainly peripheral blood and bone marrow but also from lymph nodes, spleen and other sources. The CLL patients were diagnosed according to the WHO classification with the tumor cells expressing CD5, CD23 and a low expression of surface Ig. 15 The median age at diagnosis of the patients was 62.5 years (range, 30-88 years) with a ratio of men to women of 1.7. Overall survival was available in 435 patients with a median follow-up time of 60 months (range, 1-288 months). A total of 207 healthy controls (median age 58 years, range, 24-73 years) were used to investigate the frequency of the Bax G(-248)A promoter polymorphism in the North European population.
Analysis of the Bax G(-248)A promoter polymorphism
Genomic DNA was extracted from frozen tumor cells and peripheral blood from healthy donors using standard protocols. PCR was performed to amplify a 280-bp fragment of the Bax promoter region containing the Bax G(-248)A polymorphism. The amplification reaction included 3 mM MgCl 2 , 200 mM dNTP, 0.5 U Platinum Taq DNA polymerase, 1 Â PCR buffer, 0.6 mM of each primer, 1 Â 0.1% gelatine and 100 ng DNA. The primer sequences were as follows 5 0 -TTAGAGACAAGCCTGGGCGT-3 0 and 5 0 -CAATGAGCATCTCCCGATAA-3 0 . After an initial denaturing step of 5 min at 941C, the amplification was carried out during 35 cycles of 30 s at 941C, 30 s at 481C and 30 s at 721C. In order to distinguish between different Bax (-248) alleles, the TauI restriction enzyme was used according to the manufacturer's protocol (Fermentas, Canada), as presence of the G(-248)A allele will give an additional TauI cleavage site. The digested products were separated using a GenePhor system electrophoresis unit with EPS 600 power supply (Pharmacia LKB Biotechnology, Uppsala, Sweden) on 12.5% GeneGel Excel polyacrylamide gel at 141C, 600 V, 25 mA and 15 W for 100 min. The gels were silver stained according to the manufacture's instructions (Pharmacia LKB Biotechnology). PCR products with the Bax G(-248)A polymorphism were direct sequenced in 12 samples which confirmed the results obtained by restriction fragment analysis.
Interphase cytogenetic analysis
FISH analysis of the following aberrations; 11qÀ, þ 12q, 13qÀ and 17pÀ, was performed as described previously. 14 
Assessment of V H gene mutation status
V H gene family-specific PCR amplification was performed using consensus V H /J H primers as described previously. [16] [17] [18] The PCR products were either direct sequenced or subcloned, and the sequence reactions were carried out on the automated DNA sequencer as detailed earlier. 16, 18, 19 The sequences were thereafter aligned to Ig sequences in the GenBank, V-BASE and IMGT databases; the V H gene was considered mutated when the mutation frequency differed more than 2% to the germline V H gene. The Ig sequences have been previously partly published.
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Bax expression analysis
To measure Bax expression, RNA extraction, cDNA synthesis and RQ-PCR was performed as previously described with three housekeeping genes for expression normalization (PGK1, LMNB1, ACTB). 21, 22 Primers for SYBR Green detection were used as previously described. 21 Data is given as relative Bax expression in arbitrary values.
Statistical analysis
Differences in proportions between subsets were calculated using the w 2 test or the Fisher's exact test. Overall survival and treatment-free survival was plotted using Kaplan-Meier analysis and differences between groups were evaluated using the logrank test. Overall survival was either calculated from the date of diagnosis until the last follow-up or death, or in a subanalysis, from date of first treatment until the last follow-up or death. Treatment-free survival was calculated from diagnosis to initial treatment. All statistical analysis was carried out with Statistica version 6.1 (Stat Soft, US).
Results
The Bax gene promoter polymorphism G(-248)A and relation to prognostic markers Analysis of the G(-248) polymorphic site in the promoter region of the Bax gene was carried out in 463 CLL patients, showing that 373 (81%) patients were homozygous for the G allele, 84 (18%) heterozygous for A allele and six (1%) homozygous for the A allele. Analysis of 207 healthy controls were also carried out which demonstrated that 163 (79%), 40 (19%) and four (2%) individuals had the GG, GA and AA genotype, respectively. No significant difference in allele or genotype frequency was found between the CLL patients and controls ( Table 1) .
The V H gene mutation status was determined in 455 cases with 243 cases (53%) showing unmutated V H genes and 212 (47%) mutated V H genes. In all, 243 patients were classified as stage A, 99 stage B and 55 stage C. The distribution of G(-248)A polymorphism was evenly distributed between different Binet stages as well as between the V H mutated and unmutated CLL subgroups (Table 2) .
FISH results were available in 196 patients, where 151 (77%) had the GG genotype and 45 (23%) the GA/AA genotype. Clonal aberrations including 11qÀ, þ 12q, 13qÀ and 17pÀ were detected in 72 and 76% of cases with the GG and GA/AA genotype, respectively. Although þ 12 was more frequent in the nonpolymorphic group and 17pÀ somewhat more frequent in the polymorphic subset, no significant differences in frequency of 11qÀ, þ 12, 13qÀ and 17pÀ aberrations were observed for patients with or without the polymorphism (Table 3 ). The frequency of the GA/AA genotype was higher in CLL patients with 17pÀ (4 of 10, 40%) compared to patients with 13qÀ (18 of 68, 26%), þ 12 (4 of 35, 11%), or 11qÀ (8 of 30, 27%). However, considering the low number of patients in the 17pÀ group, larger numbers have to be studied to address the significance of this finding, if any. 
The Bax promoter polymorphism and survival
The survival data was grouped into CLL patients with the GA and AA (85 cases) or GG (350 cases) Bax genotype. No significant difference in median overall survival was found between these two groups (85 and 102 months, respectively, log-rank test, P ¼ 0.21, Figure 1 ). Moreover, no significant difference in overall survival was evident when analyzing stage A and stage B/C patients separately with or without the polymorphism; median survival for stage A patients 108 and 134 months, respectively, P ¼ 0.86, and for stage B/C patients 57 and 74 months, respectively, P ¼ 0.27 (data not shown). When analyzing the subgroups defined by the V H gene mutation status, no significant difference was found for patients with mutated or unmutated V H genes with presence or absence of the Bax polymorphism (Figure 2a) . A trend towards shorter overall survival was noted in the V H mutated subgroup with the GA and AA genotype (42 cases) as compared to cases with the GG genotype (161 cases), P ¼ 0.08 (Figure 2) . However, when only analyzing mutated stage A cases (without V H 3-21 þ cases), this tendency was lost (130 with follow-up data, P ¼ 0.40, Figure 2b ). We also investigated the impact of the Bax polymorphism within the subsets with 11qÀ (8 GA/AA and 22 GG), þ 12 (4 GA and 31 GG), 13qÀ (18 GA and 50 GG) and 17pÀ (4 GA and 6 GG) aberrations, but no significant difference in overall survival was shown in any of these subgroups (data not shown).
Furthermore, because the effect of the Bax polymorphism was previously shown to be specifically pronounced in treated patients, survival analyses were performed for a subset of patients who had received at least one line of treatment and where time to initial treatment was available. Among these patients, (98 patients; 25 with polymorphism and 73 without polymorphism), the overall survival and treatment-free survival from diagnosis remained unaffected by the Bax polymorphism status; overall survival in treated patients with and without the polymorphism was 80 and 100 months, respectively, P ¼ 0.40 ( Figure 3 ) and treatment-free survival 25 and 31 months, respectively P ¼ 0.32. The overall survival from the time of first treatment was somewhat shorter for patients with the GA or AA genotype (n ¼ 25), however, this was not significantly different from patients with the GG genotype (n ¼ 73) (36 vs 63 months, log-rank test P ¼ 0.26, Figure 3b ).
Discussion
A G(-248)A polymorphism in the promoter region of the Bax gene has caught much attention lately considering the recent reports showing that this particular polymorphism was associated with advanced stage, treatment resistance and short overall survival. [8] [9] [10] However, in this report, we present data Bax promoter polymorphism in CLL Å Skogsberg et al that argues against a role for this polymorphism in the disease pathogenesis of CLL or in influencing clinical outcome. In the initial report by Saxena et al. 8 studying 34 CLL patients they demonstrated an increased genotype frequency of the Bax G(-248)A polymorphism in CLL compared to controls, particularly in patients with higher disease stage. However, our analysis of the G(-248)A polymorphism in 463 CLL patients showed that 81, 18 and 1% of cases displayed the GG, GA and AA genotypes, respectively, with no significant difference in genotype and allele frequency compared to healthy controls. In addition, no skewed distributions in genotype frequency was evident between patients with Binet stage A vs B/C, and V H mutated vs V H unmutated CLL patients. Our findings support the recent report by Starczynski et al. 10 who also could not find an increased frequency of the G(-248)A polymorphism in their entire CLL cohort, in different Binet stages or in the mutated and unmutated CLL subsets. Both our studies thus strongly argue against the importance of this polymorphism in CLL development as was initially proposed. 8 In the recent report by Starczynski et al., 10 the Bax G(-248)A polymorphism was associated with shorter overall survival in CLL. They showed this effect of the Bax polymorphism on survival in their entire material (203 patients), but it was more pronounced in CLL patients that had undergone treatment (P ¼ 0.03), in particular when analyzing overall survival from date of first treatment (P ¼ 0.012). 10 In our CLL material, no significant difference in overall survival was shown between CLL patients with or without the Bax polymorphism. Although our study cohort in general has a more aggressive clinical course than the cohort in the Starczynski study, 10 which consists of more stage A cases and CLLs with mutated V H genes, similar findings was also shown when only analyzing stage A cases. Furthermore, when combining the Bax polymorphism status and V H mutation status data, no significant difference in survival was evident within either the V H unmutated or the V H mutated subgroup for patients with and without the polymorphism. A trend of worse survival was noticed for V H mutated patients with the Bax polymorphism, but this was lost when analyzing stage A cases only. Contrary to the Starczynski study, 10 we did not find any significant difference in outcome for treated CLL patients with the Bax polymorphism. Even though the treatment strategies may have been too diverse during the last decades to draw valid conclusions as well as that the onset of treatment may have varied, our data does not seem to provide support for the observation of an inferior survival for treated CLL patients with the Bax G(-248)A polymorphism. 10 Moreover, the polymorphism did not affect outcome in subsets defined by genomic aberrations. This also argues against significance of the Bax polymorphism regarding inferior outcome after therapy, since 11qÀ and particularly 17pÀ has been associated with treatment failure in several studies. 14, 23, 24 The presence of the Bax promoter polymorphism has been correlated to reduced Bax RNA/protein expression and drug resistance. 8, 10 In contrast, although only analyzing a small subset of cases (n ¼ 35), we could not find any difference in RNA expression level between CLL tumors displaying the polymorphism or not, implying a limited effect of the Bax polymorphism for Bax expression in our material. However, this does not fully rule out the possibility that the reported decreased Bax protein levels in polymorphic CLL are caused by post-translational modification.
Taken together, the similar frequency of the Bax polymorphism in CLL and controls disaccord with the recent suggestion of a pathogenic role for the polymorphism in CLL. Furthermore, we believe that the clinical impact of the Bax polymorphism is limited, since presence of the G(-248)A polymorphism did not correlate to overall survival or known prognostic markers in this series of 463 CLL patients.
